Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that interim data from the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with de novo poor-risk acute myelogenous leukemia (AML) had been presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO(R)) in Chicago, Illinois.

At ASCO(R), data were presented in 85 evaluable patients. The median age of these patients was 73 years (range of 60-87 years). Ninety-five percent of patients had two or more risk factors associated with a poor prognosis in elderly AML and 74% had three or more risk factors. The most common risk factors were age greater than or equal to 70 (78% of patients), and cardiac and pulmonary dysfunction (73% and 76% of patients respectively). In addition, 47% of patients had unfavorable cytogenetics.

The overall complete response rate was 35% (22 CR and 8 CRp). 90% of responses occurred after first induction treatment. While follow-up is still ongoing, the median (range) of overall survival for responders was 6.3 months (1.7-16.4 months) and for all patients was 3.2 months (0.1-16.4 months).

The induction death rate within 30 days of first induction treatment was 14%. The majority of first induction deaths were either due to progression of disease or infection. Myelosuppression was the primary toxicity, with pneumonia, infection and sepsis and non-infectious pulmonary disorders (hypoxia and dyspnea) being the most common severe adverse events (greater than or equal to grade 3).

Dr. Gary Schiller, Professor of Medicine at the David Geffen School of Medicine at UCLA and a lead investigator on the study, said "The
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
(Date:12/22/2014)... , Dec. 22, 2014  Relmada Therapeutics, ... therapies for the treatment of chronic pain, announced ... been dosed in a pharmacokinetic and pharmacodynamic study ... for neuropathic pain. Racemic methadone is ... various pain states and substitution therapy in opioid ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3
... N.Y., Nov. 21, 2011  Regeneron Pharmaceuticals, Inc. (Nasdaq: ... Tessier-Lavigne, Ph.D. to fill a new seat on its ... The Rockefeller University in New York City, one of ... appointment at Rockefeller in 2011, he served as Executive ...
... 2011 Mylan Inc. (Nasdaq: MYL ) today ... Novartis Pharmaceuticals Corporation related to Vivelle-Dot® (Estradiol Transdermal ... 0.075 mg/day and 0.1 mg/day). Pursuant to ... receive a patent license to begin selling generic versions of ...
Cached Medicine Technology:Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors 2Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors 3Mylan Announces Settlement Agreement for its First-to-File Generic Version of Vivelle-Dot® 2
(Date:12/22/2014)... On December 22, 2014, My Positive Perspective ... for an episode to celebrate Christmas. At the beginning ... so important to you that we all appreciate and ... should respect who Jesus was. I think sometimes we ... That means that on Jesus’ birthday we remember that ...
(Date:12/22/2014)... China (PRWEB) December 22, 2014 Physicians ... MabThera (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), ... , a leading global healthcare consulting firm. MabThera is ... lymphoma (DLBCL), the most common form of NHL. , ... Access and Barriers,” the incidence of NHL in China ...
(Date:12/22/2014)... Florida (PRWEB) December 22, 2014 Give ... holiday season, the gift of health and vitality. , ... offering its three top-selling anti-aging formulas in special Holiday ... free rush delivery. , Each bottle contains cutting-edge, ... areas that don't work as well as we age. ...
(Date:12/22/2014)... Texas (PRWEB) December 22, 2014 7,178 ... and bustle of Black Friday shopping and opted instead ... and marketing education company, for their 5th annual “Black ... charged just $7 to attend the 5 hour ... that they promptly donated to support two Central Texas ...
(Date:12/22/2014)... NY (PRWEB) December 22, 2014 ... a 2014 Professional Woman of the Year. She is ... As the largest, most recognized networking organization of professional ... profession, the National Association of Professional Women is a ... 300 Local Chapters. , Ms. Kreider is passionate and ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Celebrates Christmas With an Event to Celebrate the Birthday of Jesus 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2
... AHA Create a Unified National Acute Coronary Syndromes ... DALLAS, May 1 The American College of,Cardiology ... Heart Association,s Get With The Guidelines(SM),(GWTG)-Coronary Artery Disease ... create a national unified registry for measuring and,improving ...
... in Product Sales Driven by Robust Growth in Clinical ... ... record revenue of $44.8 million for the first quarter,of fiscal 2008, an increase ... was $1.9 million, or $(0.03) per share, on a,GAAP basis; first quarter net ...
... seed and oil company will focus on new business development ... ULTRA low linolenic, trans fat-free products., ... an,agreement with two key venture capital firms, securing $4 million ... soybean,products. Asoyia is the innovator and leader in developing and ...
... and elsewhere report what is believed to be the ... of heart tissue and the subsequent damage leading to ... findings from the Multiethnic Study of Atherosclerosis (MESA), to ... Journal of the American College of Cardiology, appear to ...
... HILL, N.C., May 1 Leading pharmaceutical,companies ... recruitment,is part of the critical path in ... Trial Excellence: The Science and Art of ... techniques,that speed clinical trial investigator recruitment and ...
... PHILADELPHIA May 1, 2008 Shire plc ... company, announced today that it will present key ... (ADHD) treatments, lisdexamfetamine dimesylate, methylphenidate transdermal system and ... extended release, at the American Psychiatric Association (APA) ...
Cached Medicine News:Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 2Health News:The American College of Cardiology Foundation's NCDR(R) and the American Heart Association's GWTG Join Forces to Fight Heart Attacks 3Health News:Cepheid Reports Record Revenue of $44.8 Million 2Health News:Cepheid Reports Record Revenue of $44.8 Million 3Health News:Cepheid Reports Record Revenue of $44.8 Million 4Health News:Cepheid Reports Record Revenue of $44.8 Million 5Health News:Cepheid Reports Record Revenue of $44.8 Million 6Health News:Cepheid Reports Record Revenue of $44.8 Million 7Health News:Cepheid Reports Record Revenue of $44.8 Million 8Health News:Cepheid Reports Record Revenue of $44.8 Million 9Health News:Cepheid Reports Record Revenue of $44.8 Million 10Health News:Asoyia Secures Venture Capital Funding 2Health News:Asoyia Secures Venture Capital Funding 3Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 2Health News:Study in 7,000 men and women ties obesity, inflammatory proteins to heart failure risk 3Health News:Strategies for Winning Clinical Investigators in a Competitive Marketplace 2Health News:Shire to present ADHD treatments scientific data at American Psychiatric Assoc. Meeting 2
... The AFX Lens is ... for use in an air-filled ... use as a primary air-fluid ... profile and sutureless design make ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
... Chalam Flat is designed for ... and induction of posterior vitreous ... for macula whole surgery, epiretinal ... tractional epiretinal membranes. Direct image ...
... magnification and increased stereopsis, the Central Retinal ... to the equatorial regions. The Central Retinal ... in membrane peeling in proliferative vitreoretinopathy extending ... The ACS Vitrectomy Lenses from Volk can ...
Medicine Products: